Search
for
Sort by
Research 91–120 of 220
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Radioprotection of Lung Tissue by Soy Isoflavones
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines
- Formulation and optimization of folate-bovine serum albumin-coated ethoniosomes of pterostilbene as a targeted drug delivery system for lung cancer: In vitro and in vivo demonstrations
- β-sitosterol in Yijing Hugui decoction prevents cyclophosphamide-induced premature ovarian insufficiency via the AKT1/Nrf2 pathway
- The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
- Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Success and Controversy of Natural Products as Therapeutic Modulators of Wnt Signaling and Its Interplay with Oxidative Stress: Comprehensive Review Across Compound Classes and Experimental Systems
- Review of Drug Repositioning in Cancer Therapeutics
- Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
- Role of ferritin, vitamin D, and thyroid dysfunction in telogen effluvium among the hospital population in Western Saudi Arabia: a case–control study
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Biological Function of Long Non-coding RNA (LncRNA) Xist
- Chemical Composition and Biological Activities of Essential Oils of Curcuma Species
- The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
- Extracellular vesicles as human therapeutics: A scoping review of the literature
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Protein Kinase C as a Therapeutic Target
- Sebaceous Gland Atrophy in Psoriasis: An Explanation for Psoriatic Alopecia?
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Local heroes or villains: tissue-resident memory T cells in human health and disease
- TREM2 macrophages induced by human lipids drive inflammation in acne lesions
- Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers
- Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways